Le Lézard
Classified in: Health
Subject: SVY

Global Cervical Cancer Epidemiology and Patient Flow Analysis 2017-2026


DUBLIN, April 19, 2018 /PRNewswire/ --

The "Global Cervical Cancer Epidemiology and Patient Flow Analysis - 2018" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The research provides insights into Cervical Cancer epidemiology, Cervical Cancer diagnosed patients, and Cervical Cancer treatment rate for US, Japan, and EU5 countries. The research measures key indicators including prevalence of Cervical Cancer derived from epidemiological analysis, patients diagnosed with Cervical Cancer, and patients treated with a drug therapy.

The research study helps executives estimate Cervical Cancer market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.

The research provides estimates and forecasts of Cervical Cancer prevalence, Cervical Cancer diagnosis rate, and Cervical Cancer treatment rate for the period 2017 - 2026. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan.

Key Topics Covered:





1. Cervical Cancer: Disease Definition



2. Global Cervical Cancer Patient Flow


2A. Global Cervical Cancer Prevalence


2B. Global Cervical Cancer Diagnosed Patients


2C. Global Cervical Cancer Treated Patients



3. Cervical Cancer Patient Flow in the US


3A. Cervical Cancer Prevalence in the US


3B. Cervical Cancer Diagnosed Patients in the US


3C. Cervical Cancer Treated Patients in the US



4. Cervical Cancer Patient Flow in Europe


4A. Cervical Cancer Prevalence in Europe


4B. Cervical Cancer Diagnosed Patients in Europe


4C. Cervical Cancer Treated Patients in Europe



5. Cervical Cancer Patient Flow in Germany


5A. Cervical Cancer Prevalence in Germany


5B. Cervical Cancer Diagnosed Patients in Germany


5C. Cervical Cancer Treated Patients in Germany



6. Cervical Cancer Patient Flow in France


6A. Cervical Cancer Prevalence in France


6B. Cervical Cancer Diagnosed Patients in France


6C. Cervical Cancer Treated Patients in France



7. Cervical Cancer Patient Flow in Spain


7A. Cervical Cancer Prevalence in Spain


7B. Cervical Cancer Diagnosed Patients in Spain


7C. Cervical Cancer Treated Patients in Spain



8. Cervical Cancer Patient Flow in Italy


8A. Cervical Cancer Prevalence in Italy


8B. Cervical Cancer Diagnosed Patients in Italy


8C. Cervical Cancer Treated Patients in Italy



9. Cervical Cancer Patient Flow in UK


9A. Cervical Cancer Prevalence in UK


9B. Cervical Cancer Diagnosed Patients in UK


9C. Cervical Cancer Treated Patients in UK



10. Cervical Cancer Patient Flow in Japan


10A. Cervical Cancer Prevalence in Japan


10B. Cervical Cancer Diagnosed Patients in Japan


10C. Cervical Cancer Treated Patients in Japan



For more information about this report visit

https://www.researchandmarkets.com/research/j38gkw/global_cervical?w=5

Media Contact:


Research and Markets
Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 



SOURCE Research and Markets


These press releases may also interest you

at 07:10
IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two
IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") today announced that interim data from its Phase 2 clinical trial demonstrates a clinically significant reduction, approaching statistical significance, in agitation in Alzheimer's at week two...

at 07:10
Curida, Small Molecules and Biologics CDMO, Secures Private Equity Investment from Signet Healthcare Partners
Curida Holding AS ("Curida") has announced a significant growth investment from Signet Healthcare Partners ("Signet"), a New York-based healthcare private equity firm. This strategic partnership will enable Curida to accelerate its expansion plans,...

at 07:10
Orthofix Names Andres Cedron as New Chief Legal Officer
Orthofix Medical Inc. , a leading global spine and orthopedics company, today announced that Andres Cedron has joined the company as Chief Legal Officer. Cedron most recently served as Vice President and Corporate Secretary at Stryker Corporation,...

at 07:10
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
PureTech Health plc ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that enrollment has been completed in the ELEVATE IPF Phase 2b...

at 07:10
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference
United Therapeutics Corporation , a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Diego on May...

at 07:10
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for...

More news about Health...


News published on and distributed by: